A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 01 Aug 2024
Price :
$35 *
At a glance
- Drugs ISM001-055 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors InSilico Medicine
- 11 Jan 2024 Planned initiation date changed from 1 Oct 2023 to 1 Feb 2024.
- 18 Dec 2023 Status changed from not yet recruiting to recruiting.
- 07 Aug 2023 New trial record